Intellia Therapeutics stock has staged a strong rebound in the short term, yet its long term record and current valuation checks suggest the recent optimism may not line up neatly with what investors are paying for the shares.

• Over the past 5 years, Intellia Therapeutics has declined 88.7%, which places the current rally in the context of a long period of value erosion for shareholders.
• Positive Phase 3 results for lonvo z and progress toward a potential regulatory approval can support higher growth expectations, but equity funding and the execution risks around commercialising gene editing therapies may still weigh on how much value the market is willing to ascribe today.
• On Simply Wall St's broader checks, Intellia Therapeutics scores 2 out of 6 for value, which leans expensive rather than a clear bargain and points to a premium against several fundamentals.

The issue now is whether the recent share price strength in Intellia Therapeutics is already pricing in the good news, or if the stock still offers enough potential reward to compensate for the risks ahead.

Is Intellia Therapeutics Getting Expensive on Sales?

P/S is often a useful way to look at Intellia Therapeutics because the company is still loss making and investors are effectively paying for its current revenue base and pipeline potential rather than near term profits.

On this metric, Intellia Therapeutics trades on a P/S of about 35.8x, compared with a biotech industry average of roughly 12.4x and a peer average of around 19.8x. Simply Wall St's model suggests a fair P/S ratio of just 0.1x, which is far below the current level. The model is heavily penalising the company for its losses, risk profile and the quality and scale of current revenues. That figure is better read as a warning signal that the shares screen very expensive on this framework, rather than as a precise target.

Despite the strong Phase 3 data and FDA filing for lonvo z lifting sentiment around Intellia Therapeutics, the current price still reflects a steep premium to typical biotech revenue multiples.

Overall, Intellia Therapeutics stock appears expensive on the P/S multiple compared with both peers and the model's fair range.

The Intellia Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Intellia Therapeutics' valuation puzzle leaves off by spelling out what kind of future growth, margins and earnings path would need to play out for the stock to be worth materially more or less than today's price. These Narratives sit on Simply Wall St's Community page. Each one links its number to a clear view on how Intellia Therapeutics' growth, profitability and risks might evolve, giving you something concrete to revisit as new information comes through.

One of the top community narratives on Intellia Therapeutics: 36% undervalued

"Improving financial discipline, as evidenced by successful restructuring, declining GAAP operating expenses and a robust cash runway into the first half of 2027, enables Intellia to absorb increased R&D investment..."

Do you think there's more to the story for Intellia Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

For Intellia Therapeutics, the valuation picture appears overvalued on standard market multiples, with a particularly wide gap between the current P/S and what typical biotech peers trade on. That premium leaves less room for disappointment if the story around lonvo z, funding needs or commercial execution does not play out as optimists hope. The key consideration for investors is whether Intellia Therapeutics can turn its pipeline and current momentum into a revenue and margin profile that ultimately makes today’s rich sales multiple feel justified rather than stretched.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.